Harrow Health Revenue and Competitors

Location

$98.7M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Harrow Health's estimated annual revenue is currently $22.5M per year.(i)
  • Harrow Health's estimated revenue per employee is $201,000
  • Harrow Health's total funding is $98.7M.

Employee Data

  • Harrow Health has 112 Employees.(i)
  • Harrow Health grew their employee count by -7% last year.

Harrow Health's People

NameTitleEmail/Phone
1
VP FinanceReveal Email/Phone
2
DirectorReveal Email/Phone
3
Regional Business DirectorReveal Email/Phone
4
Regional Business DirectorReveal Email/Phone
5
Senior Director Supply ChainReveal Email/Phone
6
Director MarketingReveal Email/Phone
7
Director - Strategic AccountsReveal Email/Phone
8
Regional Business Director (Northeast)Reveal Email/Phone
9
Facilities Maintenance ManagerReveal Email/Phone
10
Key Account ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$84.8M42224%N/AN/A
#2
$0.4M20%N/AN/A
#3
$32M1593%N/AN/A
#4
$35M1213%$62.5MN/A
#5
$30.2M15018%N/AN/A
#6
$135.3M6730%N/AN/A
#7
$110.3M549N/AN/AN/A
#8
$60.1M299-4%N/AN/A
#9
$554.8M17252%N/AN/A
#10
$10.5M524%N/AN/A
Add Company

What Is Harrow Health?

Imprimis Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing proprietary compounded drug therapies to physicians and patients in the United States. The company owns, markets, and sells a portfolio of proprietary combination formulations in ophthalmology and urology. Its ophthalmic formulations include anti-inflammatory and anti-bacterial combination formulations, such as Tri-Moxi, a compounded formulation that is a combination of triamcinolone acetonide and moxifloxacin hydrochloride used as an injection during ocular surgery, as well as an eye drop in pre-and post-ocular surgery; and Tri-Moxi-Vanc, a compounded formulation, which is a combination of triamcinolone acetonide, moxifloxacin hydrochloride, and vancomycin used as an injection during ocular surgery. The company?s ophthalmic formulations also comprise Pred-Moxi, a compounded formulation that is a combination of prednisolone and moxifloxacin hydrochloride used as an eye drop in pre-and post-ocular surgery. Imprimis Pharmaceuticals, Inc. markets its ophthalmic formulations under the Dropless Therapy and LessDrops brands. It also offers urology formulations, including heparin and alkalinized lidocaine, a patented urologic formulation, which is delivered directly to the bladder for the treatment of interstitial cystitis; and injectable pentoxifylline formulation for the treatment of certain fibrotic conditions, including Peyronie?s disease. The company was formerly known as Transdel Pharmaceuticals, Inc. and changed its name to Imprimis Pharmaceuticals, Inc. in February 2012. Imprimis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in San Diego, California.

keywords:Sales and Marketing

$98.7M

Total Funding

112

Number of Employees

$22.5M

Revenue (est)

-7%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Harrow Health News

2022-04-20 - -$0.04 Earnings Per Share Expected for Harrow Health, Inc ...

Equities analysts expect that Harrow Health, Inc. (NASDAQ:HROW – Get Rating) will announce earnings of ($0.04) per share for the current...

2022-04-20 - -$0.04 Earnings Per Share Expected for Harrow Health, Inc ...

Equities analysts expect that Harrow Health, Inc. (NASDAQ:HROW – Get Rating) will announce earnings of ($0.04) per share for the current...

2022-04-13 - Harrow Health, Inc. (NASDAQ:HROW) Major Shareholder Buys ...

Get Harrow Health alerts: On Friday, January 28th, Opaleye Management Inc. acquired 6,343 shares of Harrow Health stock. The shares...

2022-04-13 - Harrow Health, Inc. (NASDAQ:HROW) Major Shareholder Buys ...

Get Harrow Health alerts: On Friday, January 28th, Opaleye Management Inc. acquired 6,343 shares of Harrow Health stock. The shares...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$23M1127%N/A
#2
$30.2M11213%N/A
#3
$23.5M11211%N/A
#4
$15M1127%N/A
#5
$28M11212%N/A